ENGN

enGene Therapeutics Inc.

Healthcare · Biotechnology

$114.41 sample

-1.12 (-0.97%) 1D

Market cap

$555.7B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-10

Alerts

8

Price$114.41 -2.78% 3M daily closessample

120.41112.17

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 25INSInsider sell: General Counsel
Sep 22INSInsider sell: General Counsel
Sep 15INSInsider sell: General Counsel
Sep 10SECForm 144 filed
Sep 02INSInsider sell: Director
Aug 28INSInsider buy: Director
Aug 20INSInsider sell: Director
Aug 14INSInsider sell: Director

Sign up to see the real ENGN record →

Company facts

SEC EDGAR registration

Name: enGene Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +43sample, -100 to +100
Reporting currency: USD

Who is positioning in ENGN

sample

Insiders: 25 insider transactions over 90 days, net selling, $539.6M
Congress: 4 members traded over 90 days
Institutions · 13F: 12 funds hold $13.9B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$36.5B +17.2% y/y

Q4 2024Q3 2026

Inventory$22.2B +21.6% y/y

Q4 2024Q3 2026

Accounts receivable$15.6B +13.0% y/y

Q4 2024Q3 2026

Total debt$41.7B +6.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $258.2B +1.0% 3M
Sample peer B: $137.0B +2.6% 3M
Sample peer C: $493.5B +3.1% 3M
Sample peer D: $498.7B -7.4% 3M
Sample peer E: $217.6B +15.8% 3M